Beam’s One-Shot Gene Editor Let Patients Go Longer Between Meals

BEAM-301 is a one-time infusion that edits DNA in the liver. Six patients took part: three at 20 mg and three at 40 mg. One 40 mg patient has too little follow-up to judge.

Patients went longer before blood sugar fell. At 20 mg, the median time rose from 2.9 to 4.3 hours by day 36. Both measurable 40 mg patients reached the trial’s 15-hour limit, and their cornstarch doses fell 71% and 92%.

Every patient had a side effect linked to treatment. Five serious events were reported, including three severe infusion reactions. They cleared in 2 to 10 days. This counts events, not patients.

A rival has arrived: Ultragenyx’s gene therapy GENGLYCOS won early FDA approval for the same disease in August 2026.

The data stop at 26 June. More results are due at an investor webcast on 27 October and a conference poster on 28 October.

On 13 October 2026, Beam shared early results from its trial of BEAM-301 in GSDIa. It is an early-stage (Phase 1/2) trial.

The trial is open-label. Patients and doctors know which dose each person gets.

More data are coming. A webcast is on Tuesday 27 October at 8:00 a.m. Eastern. The full poster is at a European gene therapy conference in Hamburg on Wednesday 28 October. Beam says updated data will be shown, so these numbers may move.

Note the timing. The data stop at 26 June, nearly four months ago. Follow-up is uneven: a median of 313 days at 20 mg but only 53 days (range 5 to 110) at 40 mg.

Time until blood sugar fell. Before treatment, the median was 2.9 hours at 20 mg and 2.5 hours at 40 mg. By day 36 the 20 mg group reached 4.3 hours. Both measurable 40 mg patients reached at least 15 hours, the trial’s limit, so their true time is unknown.

Cornstarch doses. At 20 mg, prescribed doses fell 74% (day 128), 71% (day 227) and 11% (day 387). At 40 mg, they fell 71% (day 50) and 92% (day 93). These come from different follow-up times, so do not read them as one patient fading. We need patient-by-patient data to judge how long the benefit lasts.

Safety. All six patients had a side effect linked to treatment. Five serious events were reported, including three severe infusion reactions, and they cleared in 2 to 10 days. Beam thinks a shorter-acting steroid given beforehand may have played a part, and says it has changed the plan. Liver enzyme rises were short-lived. There were no dose-limiting toxicities, treatment stops for side effects, or deaths.

The disease. A gene called G6PC1 makes an enzyme the liver needs to release sugar into the blood. In GSDIa the enzyme works poorly, so fasting becomes dangerous. BEAM-301 targets one common error called R83C, so it is not a treatment for every form of GSDIa.

The tool and the delivery. Standard CRISPR cuts DNA. A base editor changes one letter without cutting through. BEAM-301 packs its editing tools in a tiny fat bubble (a lipid nanoparticle) that heads for the liver. Reaching other organs is harder, as an AI-designed protein shell that reached the lungs showed. A lasting edit could mean lasting benefit, but that still has to be shown in patients.

GSDIa now has an approved gene therapy. On 19 August 2026 the FDA gave early (“accelerated”) approval to Ultragenyx’s GENGLYCOS for patients aged 8 and over. It uses a harmless virus (AAV8) to deliver a working copy of the gene.

It has bigger trial data. A 48-week trial of 46 people, randomised and double-blind, showed lower cornstarch needs. The approval is to reduce cornstarch use alongside diet. Early approval means the company must still confirm the benefit.

It sets a benchmark, not a path. Less cornstarch is now an accepted goal, but that does not tell us how BEAM-301 will be judged.

Its limit may be Beam’s opening. Some patients carry antibodies to the AAV8 virus and may not be eligible. A bubble-delivered editor might help them, though six patients cannot prove that or show it is better or safer.

Beam is entering a crowded field with six patients against a larger controlled trial.

Beam Therapeutics (NASDAQ: BEAM) develops BEAM-301. Ultragenyx (NASDAQ: RARE) holds the approved rival therapy.

The question for investors is whether this editing approach can give lasting benefit with acceptable safety. Beam has not described a late-stage trial plan or launch timetable for BEAM-301.

Six patients cannot set a market value. Investors would want longer follow-up, a chosen dose, a clear plan and proof it stands out from the approved option.

Big drug companies are paying for gene editing. Lilly agreed in June 2025 to buy Verve for up to $1.3 billion. That shows interest in the field, not that BEAM-301 will succeed.

Very small and uneven. Six patients, everyone knew the dose, and follow-up was short. Only two are measurable at 40 mg, with a median follow-up of 53 days for that group. Cornstarch doses were adjusted by people who knew the treatment and the glucose readings.

The fast test is capped at 15 hours, which hides how long patients could really go.

Lasting benefit is unproven. The different cornstarch cuts come from different follow-up days. They do not show that one patient’s benefit faded. We need patient-by-patient results.

Safety needs a close look. Every patient had a treatment-linked side effect. The release has no results yet from patients on the new steroid plan and does not describe two of the five serious events.

This is a company release, not a peer-reviewed study, and we found no outside expert quoted in any coverage. The independent write-up, CRISPR Medicine News, passes on Beam’s numbers. For how carefully to read company-reported gene therapy wins, see the Beacon gene-therapy result Biogen and J&J could not match.

27 October webcast and 28 October poster: new results, longer follow-up and details of the serious events.

Dose and path: which dose goes forward, and any plan for a larger approval trial or special FDA status.

The new steroid plan: do infusion reactions fall?

Patient-by-patient results at both doses, including why one 20 mg result was only an 11% cut at day 387.

GENGLYCOS launch: price, uptake, and how many patients AAV8 antibodies rule out.

Beam press release, 13 October 2026 (GlobeNewswire): trial design, results, safety, follow-up and upcoming events.

CRISPR Medicine News: independent trade write-up; passes on company data.

Beam Q2 2026 financial results: extra company and pipeline background.

Goodwin note on GENGLYCOS approval: approval basis, label and follow-up requirements.

Pharmaceutical Technology on GENGLYCOS: second report of the 19 August approval.

BioSpace on Lilly and Verve: deal terms and analyst doubts.

AAII on Beam stock: market background only; no price figures are used in this article.